Yumeng Li
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Yumeng Li has a total of 19 co-authors. Here are the top co-authors by number of shared publications:
Hongling Jia
The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan 250014, China
2 shared publicationsBizhu Zhao
Clinical Medicine, The First Clinical School of Zhengzhou University, Zhengzhou, Henan, China
1 shared publicationDong Guo
Clinical Medicine, The First Clinical School of Zhengzhou University, Zhengzhou, Henan, China
1 shared publication- Fu Zhao
The First Clinical Medical College of Shandong University of Traditional Chinese Medicine, Jinan 250014, China
1 shared publication Gaofeng Ni
Department of Breast Surgery, Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai 264003, China
1 shared publication- Hongyan Zang
Department of Breast Surgery, Yantaishan Hospital Affiliated to Binzhou Medical University, Yantai, China
1 shared publication
Latest Publications
- Open Access
- 27 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1649147
Targeted and personalized immunotherapy in lung adenocarcinoma: single-cell RNA sequencing of MAFF+ tumor cells and the therapeutic potential of FOS
Background: Non-small cell lung cancer (NSCLC) was a major cause of cancer-related mortality globally. Despite advancements in immunotherapy and targeted therapies, clinical outcomes were still limited by tumor heterogeneity and treatment resistance. The transcription factor (TF) FOS, a key component of the AP-1 complex, was linked to tumor progression and therapy resistance in various cancers, but its precise mechanisms remained unclear, and its role in lung adenocarcinoma (LUAD) was unknown. We investigated the tumor microenvironment (TME) of LUAD using single-cell RNA sequencing (scRNA-seq) to identify potential therapeutic vulnerabilities and FOS-driven mechanisms.Methods: We identified fourteen cell types by analyzing scRNA-seq data from LUAD samples (GSE164789) using Seurat (v4.4.0) and Harmony for batch correction. InferCNV was utilized to characterize the tumor cell subtypes after they were clustered using marker genes. CytoTRACE and Monocle were used to create pseudotime trajectories in order to map differentiation states. CellChat revealed intercellular communication networks, while SCENIC identified TF regulatory modules. The CCK-8, Edu, Transwell, and wound healing assays showed that FOS knockdown functionally validated A549 and NCI-H1975 cells. Furthermore, a prognostic model was developed.Results: We discovered that invasive LUAD was dominated by a highly stem-like C0 MAFF+ tumor cell subtype that produced chemokines and activated lipid metabolism. These cells stimulated immunosuppression and tumor-associated macrophage (TAM) differentiation by interacting with macrophages via MIF-(CD74+CD44) signaling. Experiments using FOS knockdown demonstrated its role in maintaining invasion, migration, and proliferation. Using the MTRS model, patients were categorized into high- and low-risk cohorts, high-risk patients exhibited unique drug sensitivities. Immunoprofile analysis revealed higher M1 macrophages in high-risk patients, suggesting that FOS inhibition could repolarize TAMs and enhance immunotherapies.Conclusion: Our studies show that FOS is a main regulator of C0 MAFF+ TCs in LUAD, polarizing macrophages via MIF and rewiring lipid metabolism to support cancer. The MTRS model offers clinical value for risk assessment even if FOS inhibition shows promise as a therapeutic approach to raise immunotherapy efficacy. Targeting the FOS could cause TME immunosuppression to be disrupted, thus LUAD presents a fresh precision oncology approach.
- 27 August 2025
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 16, 1649147
Open AccessTargeted and personalized immunotherapy in lung adenocarcinoma: single-cell RNA sequencing of MAFF+ tumor cells and the therapeutic potential of FOS
Background: Non-small cell lung cancer (NSCLC) was a major cause of cancer-related mortality globally. Despite advancements in immunotherapy and targeted therapies, clinical outcomes were still limited by tumor heterogeneity and treatment resistance. The transcription factor (TF) FOS, a key component of the AP-1 complex, was linked to tumor progression and therapy resistance in various cancers, but its precise mechanisms remained unclear, and its role in lung adenocarcinoma (LUAD) was unknown. We investigated the tumor microenvironment (TME) of LUAD using single-cell RNA sequencing (scRNA-seq) to identify potential therapeutic vulnerabilities and FOS-driven mechanisms.Methods: We identified fourteen cell types by analyzing scRNA-seq data from LUAD samples (GSE164789) using Seurat (v4.4.0) and Harmony for batch correction. InferCNV was utilized to characterize the tumor cell subtypes after they were clustered using marker genes. CytoTRACE and Monocle were used to create pseudotime trajectories in order to map differentiation states. CellChat revealed intercellular communication networks, while SCENIC identified TF regulatory modules. The CCK-8, Edu, Transwell, and wound healing assays showed that FOS knockdown functionally validated A549 and NCI-H1975 cells. Furthermore, a prognostic model was developed.Results: We discovered that invasive LUAD was dominated by a highly stem-like C0 MAFF+ tumor cell subtype that produced chemokines and activated lipid metabolism. These cells stimulated immunosuppression and tumor-associated macrophage (TAM) differentiation by interacting with macrophages via MIF-(CD74+CD44) signaling. Experiments using FOS knockdown demonstrated its role in maintaining invasion, migration, and proliferation. Using the MTRS model, patients were categorized into high- and low-risk cohorts, high-risk patients exhibited unique drug sensitivities. Immunoprofile analysis revealed higher M1 macrophages in high-risk patients, suggesting that FOS inhibition could repolarize TAMs and enhance immunotherapies.Conclusion: Our studies show that FOS is a main regulator of C0 MAFF+ TCs in LUAD, polarizing macrophages via MIF and rewiring lipid metabolism to support cancer. The MTRS model offers clinical value for risk assessment even if FOS inhibition shows promise as a therapeutic approach to raise immunotherapy efficacy. Targeting the FOS could cause TME immunosuppression to be disrupted, thus LUAD presents a fresh precision oncology approach.
- Open Access
- 13 January 2025
- Published by Elsevier in Translational Oncology
- Vol. 52, 102280
MAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy
- 13 January 2025
- Published by Elsevier in Translational Oncology
- Vol. 52, 102280
Open AccessMAZ-mediated tumor progression and immune evasion in hormone receptor-positive breast cancer: Targeting tumor microenvironment and PCLAF+ subtype-specific therapy
- Open Access
- 3 December 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1485109
A new perspective on macrophage-targeted drug research: the potential of KDELR2 in bladder cancer immunotherapy
Introduction: Bladder cancer was recognized as one of the most common malignant tumors in the urinary system, and treatment options remained largely limited to conventional surgery, radiotherapy, and chemotherapy, which limited patient benefits.Methods: Researchers constructed an RNA transcriptome map of bladder cancer by integrating single-cell RNA sequencing and clinical data, identifying potential molecular targets for diagnosis and treatment. We also verified the antitumor activity of the target through in vitro experiment.Results: A distinct tumor cell subpopulation characterized by elevated S100A8 expression exhibited high copy number variation, high stemness, and low differentiation. It interacted with myeloid cells via the MIF-(CD74+CD44) and MIF-(CD74+CXCR4) signaling pathways. This study underscored KDELR2’s role in promoting cell proliferation, invasion, and migration, providing new therapeutic insights. Prognostic analysis revealed that KDELR2 correlated with poor survival, higher immune scores, and increased macrophage infiltration.Discussion: The findings suggested that patients with high KDELR2 expression might benefit from immune checkpoint therapy. KDELR2 was also shown to enhance bladder cancer cell proliferation, invasion, and migration, highlighting it as a promising target for macrophage-focused drug development.
- 3 December 2024
- Published by Frontiers Media SA in Frontiers in Immunology
- Vol. 15, 1485109
Open AccessA new perspective on macrophage-targeted drug research: the potential of KDELR2 in bladder cancer immunotherapy
Introduction: Bladder cancer was recognized as one of the most common malignant tumors in the urinary system, and treatment options remained largely limited to conventional surgery, radiotherapy, and chemotherapy, which limited patient benefits.Methods: Researchers constructed an RNA transcriptome map of bladder cancer by integrating single-cell RNA sequencing and clinical data, identifying potential molecular targets for diagnosis and treatment. We also verified the antitumor activity of the target through in vitro experiment.Results: A distinct tumor cell subpopulation characterized by elevated S100A8 expression exhibited high copy number variation, high stemness, and low differentiation. It interacted with myeloid cells via the MIF-(CD74+CD44) and MIF-(CD74+CXCR4) signaling pathways. This study underscored KDELR2’s role in promoting cell proliferation, invasion, and migration, providing new therapeutic insights. Prognostic analysis revealed that KDELR2 correlated with poor survival, higher immune scores, and increased macrophage infiltration.Discussion: The findings suggested that patients with high KDELR2 expression might benefit from immune checkpoint therapy. KDELR2 was also shown to enhance bladder cancer cell proliferation, invasion, and migration, highlighting it as a promising target for macrophage-focused drug development.